Related Experiment Video

Updated: Jul 6, 2025

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

724

NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells

Allyson McCune1, Jacki Kornbluth1,2

  • 1Department of Pathology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.

Cancers
|January 11, 2024
PubMed

Insights

Extracellular vesicles (EVs) derived from natural killer (NK) cells show potent anti-cancer activity. These NK3.3EVs effectively kill drug-resistant leukemia and breast cancer cells, including cancer stem cells, by inducing apoptosis.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cell Biology

Background:

  • Cancer treatment resistance, metastasis, and relapse are significant clinical challenges.
  • Therapeutic limitations include poor drug penetration into tumor tissues and the presence of cancer stem cells (CSCs).
  • Extracellular vesicles (EVs) derived from natural killer (NK) cells (NK3.3EVs) have previously demonstrated cytotoxic effects against cancer cell lines.

Purpose of the Study:

  • To evaluate the efficacy of NK3.3EVs in a more physiologically relevant 3D breast cancer model.
  • To determine if NK3.3EVs can overcome chemoresistance in leukemia cells.
  • To assess the impact of NK3.3EVs on cancer stem cell populations.

Main Methods:

  • Utilized a 3D MCF7 breast cancer mammosphere model to simulate in vivo conditions.
  • Generated an imatinib-resistant K562 chronic myeloid leukemia (CML) cell line for drug resistance studies.
  • Assessed NK3.3EVs' cytotoxicity, apoptosis induction (caspase-3/-7 activation), and effects on CSC markers (CD34+/CD38-) and gene expression.

Main Results:

  • NK3.3EVs successfully penetrated MCF7 mammospheres and induced apoptosis.
  • NK3.3EVs exhibited enhanced cytotoxicity against imatinib-resistant K562 cells compared to parental cells, triggering apoptosis.
  • NK3.3EVs reduced the CSC subpopulation and CSC-associated gene expression in K562 cells.

Conclusions:

  • NK3.3EVs demonstrate significant therapeutic potential against resistant and stem-like cancer cells.
  • NK3.3EVs show promise as an immunotherapeutic agent for challenging cancer types.
  • The ability of NK3.3EVs to overcome drug resistance and target CSCs warrants further investigation.
Keywords:
breast cancercancer stem cellsextracellular vesiclesleukemianatural killer

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.6K
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.4K

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
921
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527